Sarah M Kashanian1, Noa G Holtzman2,3, Ciera L Patzke3,4, Jonathan Cornu4, Alison Duffy3,4,5, Madhurima Koka6, Sandrine Niyongere1,3, Vu H Duong1,3, Maria R Baer1,3, Jummai Apata7, Farin Kamangar8, Ashkan Emadi9,10,11. 1. Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. 2. Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 3. Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22 South Greene Street, Room N9E06, Baltimore, MD, 21201, USA. 4. Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD, USA. 5. University of Maryland School of Pharmacy, Baltimore, MD, USA. 6. Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA. 7. Center for Urban Health Disparities Research and Innovation, Morgan State University, Baltimore, MD, USA. 8. Department of Biology, School of Computer, Mathematical, and Natural Sciences, Morgan State University, Baltimore, MD, USA. 9. Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. aemadi@umm.edu. 10. Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22 South Greene Street, Room N9E06, Baltimore, MD, 21201, USA. aemadi@umm.edu. 11. Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA. aemadi@umm.edu.
Abstract
PURPOSE: Asparaginases, key agents in treatment of acute lymphoblastic leukemia (ALL), are associated with venous thromboembolism (VTE). While risks of short-acting asparaginase-related VTE is well-known, we studied VTE incidence and risk factors in adult ALL patients treated with and without long-acting pegylated asparaginase (PegA). METHODS: Single-center, retrospective analysis of 89 ALL patients treated with (n = 61) or without (n = 28) PegA at Greenebaum Comprehensive Cancer Center. Reviewed patient and disease characteristics, treatment, and VTE incidence. RESULTS: VTE during treatment occurred in 31 patients (35%), and was associated with PegA (p = 0.001) and Philadelphia chromosome negativity (p = 0.002). Among PegA recipients, VTE was associated with a significantly higher mean body mass index (BMI) of 31.3 kg/m2 (p = 0.037), and was more common with pre-T/T cell compared to pre-B/B cell ALL (68.2% vs. 33.3%, p = 0.009). Antithrombin-III (ATIII) levels were measured for 26 patients; 16 (61.5%) were < 50%. Of those, 8 (50%) experienced VTE, while 3 of 10 (30%) patients with ATIII levels ≥ 50% experienced VTE. VTE occurred in 7 of 13 (54%) of patients who received ATIII repletion. There was a trend toward a higher incidence of VTE in the PegA group among patients with non-O compared to O blood type (55.9% vs. 33.3%, p = 0.079) as well as those with a higher hemoglobin at diagnosis (9.3 vs 8.1 g/dL, p = 0.056). CONCLUSION: This study confirms PegA as a risk factor for VTE in patients with ALL. Risk factors among those receiving PegA include higher BMI and pre-T/T cell ALL. ATIII repletion was not shown to be protective against VTE. There was a higher incidence of VTE in patients who received PegA with non-O compared to O blood type, but the precise correlation is uncertain.
PURPOSE: Asparaginases, key agents in treatment of acute lymphoblastic leukemia (ALL), are associated with venous thromboembolism (VTE). While risks of short-acting asparaginase-related VTE is well-known, we studied VTE incidence and risk factors in adult ALL patients treated with and without long-acting pegylated asparaginase (PegA). METHODS: Single-center, retrospective analysis of 89 ALL patients treated with (n = 61) or without (n = 28) PegA at Greenebaum Comprehensive Cancer Center. Reviewed patient and disease characteristics, treatment, and VTE incidence. RESULTS:VTE during treatment occurred in 31 patients (35%), and was associated with PegA (p = 0.001) and Philadelphia chromosome negativity (p = 0.002). Among PegA recipients, VTE was associated with a significantly higher mean body mass index (BMI) of 31.3 kg/m2 (p = 0.037), and was more common with pre-T/T cell compared to pre-B/B cell ALL (68.2% vs. 33.3%, p = 0.009). Antithrombin-III (ATIII) levels were measured for 26 patients; 16 (61.5%) were < 50%. Of those, 8 (50%) experienced VTE, while 3 of 10 (30%) patients with ATIII levels ≥ 50% experienced VTE. VTE occurred in 7 of 13 (54%) of patients who received ATIII repletion. There was a trend toward a higher incidence of VTE in the PegA group among patients with non-O compared to O blood type (55.9% vs. 33.3%, p = 0.079) as well as those with a higher hemoglobin at diagnosis (9.3 vs 8.1 g/dL, p = 0.056). CONCLUSION: This study confirms PegA as a risk factor for VTE in patients with ALL. Risk factors among those receiving PegA include higher BMI and pre-T/T cell ALL. ATIII repletion was not shown to be protective against VTE. There was a higher incidence of VTE in patients who received PegA with non-O compared to O blood type, but the precise correlation is uncertain.
Authors: Meir Wetzler; Ben L Sanford; Joanne Kurtzberg; Divino DeOliveira; Stanley R Frankel; Bayard L Powell; Jonathan E Kolitz; Clara D Bloomfield; Richard A Larson Journal: Blood Date: 2007-01-30 Impact factor: 22.113
Authors: Stuart E Siegel; Anjali Advani; Nita Seibel; Lori Muffly; Wendy Stock; Selina Luger; Bijal Shah; Daniel J DeAngelo; David R Freyer; Dan Douer; Rebecca H Johnson; Brandon Hayes-Lattin; Mark Lewis; Jerry J Jaboin; Peter F Coccia; Archie Bleyer Journal: Am J Hematol Date: 2018-09-03 Impact factor: 10.047
Authors: Vassilios I Avramis; Susan Sencer; Antonia P Periclou; Harland Sather; Bruce C Bostrom; Lewis J Cohen; Alice G Ettinger; Lawrence J Ettinger; Janet Franklin; Paul S Gaynon; Joanne M Hilden; Beverly Lange; Fataneh Majlessipour; Pracad Mathew; Michael Needle; Joseph Neglia; Gregory Reaman; John S Holcenberg; Linda Stork Journal: Blood Date: 2002-03-15 Impact factor: 22.113
Authors: Andrew E Place; Kristen E Stevenson; Lynda M Vrooman; Marian H Harris; Sarah K Hunt; Jane E O'Brien; Jeffrey G Supko; Barbara L Asselin; Uma H Athale; Luis A Clavell; Peter D Cole; Kara M Kelly; Caroline Laverdiere; Jean-Marie Leclerc; Bruno Michon; Marshall A Schorin; Jennifer J G Welch; Steven E Lipshultz; Jeffery L Kutok; Traci M Blonquist; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman Journal: Lancet Oncol Date: 2015-11-06 Impact factor: 41.316
Authors: D J DeAngelo; K E Stevenson; S E Dahlberg; L B Silverman; S Couban; J G Supko; P C Amrein; K K Ballen; M D Seftel; A R Turner; B Leber; K Howson-Jan; K Kelly; S Cohen; J H Matthews; L Savoie; M Wadleigh; L A Sirulnik; I Galinsky; D S Neuberg; S E Sallan; R M Stone Journal: Leukemia Date: 2014-07-31 Impact factor: 11.528